65 related articles for article (PubMed ID: 38494863)
1. Mechanistic basis of co-stimulatory CD40-CD40L ligation mediated regulation of immune responses in cancer and autoimmune disorders.
Chand Dakal T; Dhabhai B; Agarwal D; Gupta R; Nagda G; Meena AR; Dhakar R; Menon A; Mathur R; Mona ; Yadav V; Sharma A
Immunobiology; 2020 Mar; 225(2):151899. PubMed ID: 31899051
[TBL] [Abstract][Full Text] [Related]
2. The role of CD40 ligand in costimulation and T-cell activation.
Grewal IS; Flavell RA
Immunol Rev; 1996 Oct; 153():85-106. PubMed ID: 9010720
[TBL] [Abstract][Full Text] [Related]
3. CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling.
Naseri S; Cordova MM; Wenthe J; Lövgren T; Eriksson E; Loskog A; Ullenhag GJ
J Cell Mol Med; 2024 Apr; 28(7):e18162. PubMed ID: 38494863
[TBL] [Abstract][Full Text] [Related]
4. IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1.
Eriksson E; Milenova I; Wenthe J; Moreno R; Alemany R; Loskog A
J Immunol; 2019 Feb; 202(3):787-798. PubMed ID: 30617223
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene.
Fernandes MS; Gomes EM; Butcher LD; Hernandez-Alcoceba R; Chang D; Kansopon J; Newman J; Stone MJ; Tong AW
Clin Cancer Res; 2009 Aug; 15(15):4847-56. PubMed ID: 19622582
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells.
Pandey MS; Wang C; Umlauf S; Lin S
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768776
[TBL] [Abstract][Full Text] [Related]
7. Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40.
Wenthe J; Naseri S; Hellström AC; Wiklund HJ; Eriksson E; Loskog A
Cancer Gene Ther; 2020 Dec; 27(12):948-959. PubMed ID: 32355275
[TBL] [Abstract][Full Text] [Related]
8. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
[TBL] [Abstract][Full Text] [Related]
9. Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition.
Wenthe J; Naseri S; Hellström AC; Moreno R; Ullenhag G; Alemany R; Lövgren T; Eriksson E; Loskog A
Mol Ther Oncolytics; 2022 Mar; 24():429-442. PubMed ID: 35141399
[TBL] [Abstract][Full Text] [Related]
10. Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy.
Yan C; Richmond A
Mol Cancer; 2021 Nov; 20(1):146. PubMed ID: 34758832
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic Adenovirus: Prospects for Cancer Immunotherapy.
Zhao Y; Liu Z; Li L; Wu J; Zhang H; Zhang H; Lei T; Xu B
Front Microbiol; 2021; 12():707290. PubMed ID: 34367111
[TBL] [Abstract][Full Text] [Related]
12. Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade.
Yan C; Saleh N; Yang J; Nebhan CA; Vilgelm AE; Reddy EP; Roland JT; Johnson DB; Chen SC; Shattuck-Brandt RL; Ayers GD; Richmond A
Mol Cancer; 2021 Jun; 20(1):85. PubMed ID: 34092233
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells.
Farrukh H; El-Sayes N; Mossman K
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34063096
[TBL] [Abstract][Full Text] [Related]
14. Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes.
Labani-Motlagh A; Naseri S; Wenthe J; Eriksson E; Loskog A
Mol Ther Oncolytics; 2021 Mar; 20():508-518. PubMed ID: 33738337
[TBL] [Abstract][Full Text] [Related]
15. Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy.
Wenthe J; Naseri S; Labani-Motlagh A; Enblad G; Wikström KI; Eriksson E; Loskog A; Lövgren T
Cancer Immunol Immunother; 2021 Oct; 70(10):2851-2865. PubMed ID: 33666760
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
